作者: Richard J. Robbins , Chee-Yeung Chan , R. Michael Tuttle , Steven M. Larson
DOI: 10.1016/S1569-2566(04)04006-2
关键词: Thyroid carcinoma 、 Positron emission tomography 、 Disease 、 FDG-Positron Emission Tomography 、 Symporter 、 Pathology 、 Medicine 、 Thyroid cancer 、 Pathological 、 Iodine
摘要: Publisher Summary This chapter describes the role of fluoro-deoxy glucose (FDG) positron emission tomography (PET) in management differentiated thyroid cancer. More than 70% deaths occur individuals whose initial histology is well-differentiated carcinoma. The current prognostic scoring systems, which utilize clinical and pathological information obtained at time diagnosis, have been very useful. major limitation their inability to predict outcome patients when, years later, they are discovered harbor metastases. particularly important as it well known that there a highly variable trajectory disease such patients. use FDG-PET scanning for evaluating with DTC has added understanding this protean disease. Metastatic lesions contain predominantly clones functional sodium–iodide symporter (NIS) transport radioactive iodine (RAI). less cannot effectively trap but much higher metabolic activity high FDG-avidity. Sensitivity RAI therapy also explained chapter.